These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 868908)

  • 1. Amikacin therapy for gram-negative septicemia.
    Meyer RD; Lewis RP; Finegold SM
    Am J Med; 1977 Jun; 62(6):930-5. PubMed ID: 868908
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Amikacin therapy of gram-negative bacteremia.
    Tally FP; Gorbach SL
    Am J Med; 1977 Jun; 62(6):936-9. PubMed ID: 868909
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Amikacin therapy for serious gram-negative bacillary infections.
    Meyer RD; Lewis RP; Carmalt ED; Finegold SM
    Ann Intern Med; 1975 Dec; 83(6):790-800. PubMed ID: 1200524
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antimicrobial spectrum, pharmacology, adverse effects, and therapeutic use of amikacin sulfate.
    Pien FD; Ho PW
    Am J Hosp Pharm; 1981 Jul; 38(7):981-9. PubMed ID: 7020413
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Review of 152 patients with bacteremias treated with amikacin.
    Tally FP; Gorbach SL
    Am J Med; 1977 Jun; 62(6):940-4. PubMed ID: 868910
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Controlled comparison of amikacin and gentamicin.
    Smith CR; Baughman KL; Edwards CQ; Rogers JF; Lietman PS
    N Engl J Med; 1977 Feb; 296(7):349-53. PubMed ID: 319355
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Amikacin therapy of gram-negative bacteremia and meningitis. Treatment in diseases due to multiple resistant bacilli.
    Sklaver AR; Greenman RL; Hoffman TA
    Arch Intern Med; 1978 May; 138(5):713-6. PubMed ID: 348135
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Amikacin therapy. Use against infections caused by gentamicin- and tobramycin-resistant organisms.
    Yu VL; Rhame FS; Pesanti EL; Axline SG
    JAMA; 1977 Aug; 238(9):943-7. PubMed ID: 328950
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Amikacin therapy for serious gram-negative infection.
    Pollock AA; Berger SA; Richmond AS; Simberkoff MS; Rahal JJ
    JAMA; 1977 Feb; 237(6):562-4. PubMed ID: 576282
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Amikacin therapy for severe gram-negative sepsis: efficacy in infections involving gentamicin-resistant organisms.
    Tally FP; Louie TJ; O'Keefe P; Gorbach SL; Bartlett JG
    J Infect Dis; 1976 Nov; 134 SUPPL():S428-32. PubMed ID: 993634
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Treatment of hospital-acquired urinary infections with amikacin (author's transl)].
    Weidner W; Nöske HD; Sziegoleit A; Schröder R; Leidenfrost U
    Med Klin; 1979 Jul; 74(27):1071-6. PubMed ID: 470792
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative efficacy and toxicity of amikacin/carbenicillin versus gentamicin/carbenicillin in leukopenic patients: a randomized prospective trail.
    Lau WK; Young LS; Black RE; Winston DJ; Linne SR; Weinstein RJ; Hewitt WL
    Am J Med; 1977 Jun; 62(6):959-66. PubMed ID: 586099
    [No Abstract]   [Full Text] [Related]  

  • 13. Gentamicin-resistant bacillary infection. Clinical features and amikacin therapy.
    Leonard JM; McGee ZA; Alford RH
    Arch Intern Med; 1978 Feb; 138(2):201-5. PubMed ID: 415674
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Amikacin in treatment of infections caused by gram-negative bacteria resistant to gentamicin and other aminoglycosides: clinical and bacteriologic results.
    Daikos GK; Kosmidis JC; Hamilton-Miller JM; Brumfitt W
    J Infect Dis; 1976 Nov; 134 SUPPL():S286-90. PubMed ID: 993623
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ototoxicity and nephrotoxicity of amikacin: an overview of phase II and phase III experience in the United States.
    Lane AZ; Wright GE; Blair DC
    Am J Med; 1977 Jun; 62(6):911-8. PubMed ID: 868905
    [No Abstract]   [Full Text] [Related]  

  • 16. Amikacin therapy for severe gram-negative sepsis. Emphasis on infections with gentamicin-resistant organisms.
    Tally FP; Louie TJ; Weinstein WM; Bartlett JG; Gorbach SL
    Ann Intern Med; 1975 Oct; 83(4):484-8. PubMed ID: 1101761
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Amikacin therapy of severe infections produced by gram-negative bacilli resistant to gentamicin.
    Valdivieso M; Bodey GP
    Am J Med Sci; 1977; 273(2):177-84. PubMed ID: 860733
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Amikacin therapy of serious gram-negative bacillary infections in chronic hemodialysis patients.
    Meyer RD; Lewis RP; Finegold SM
    Chemotherapy; 1978; 24(3):172-8. PubMed ID: 657877
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A double beta-lactam combination versus an aminoglycoside-containing regimen as empiric antibiotic therapy for febrile granulocytopenic cancer patients.
    De Jongh CA; Joshi JH; Thompson BW; Newman KA; Finley RS; Moody MR; Salvatore PC; Tenney JH; Drusano GL; Schimpff SC
    Am J Med; 1986 May; 80(5C):101-11. PubMed ID: 3521269
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative effectiveness of combinations of amikacin with penicillin G and amikacin with carbenicillin in gram-negative septicemia: double-blind clinical trial.
    Klastersky J; Hensgens C; Meunier-Carpentier F
    J Infect Dis; 1976 Nov; 134 SUPPL():S433-40. PubMed ID: 792359
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.